Bert Klebl

6.3k total citations · 1 hit paper
71 papers, 3.4k citations indexed

About

Bert Klebl is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Bert Klebl has authored 71 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 21 papers in Oncology and 15 papers in Epidemiology. Recurrent topics in Bert Klebl's work include Cancer-related Molecular Pathways (7 papers), Cytomegalovirus and herpesvirus research (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Bert Klebl is often cited by papers focused on Cancer-related Molecular Pathways (7 papers), Cytomegalovirus and herpesvirus research (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Bert Klebl collaborates with scholars based in Germany, United States and Norway. Bert Klebl's co-authors include Anil Koul, Jan Eickhoff, Thomas Herget, Axel Ullrich, Gerhard Müller, Axel Choidas, Peter Habenberger, Liem Nguyen, Giorgio Ferrari and Jean Pieters and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Bert Klebl

70 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gasdermin D plays a vital role in the generation of neutrophil extracellular traps

2018 571 citations Gabriel Sollberger, Axel Choidas et al. Science Immunology profile →

Peers

Countries citing papers authored by Bert Klebl

Since Specialization

Citations

This map shows the geographic impact of Bert Klebl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bert Klebl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bert Klebl more than expected).

Fields of papers citing papers by Bert Klebl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bert Klebl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bert Klebl. The network helps show where Bert Klebl may publish in the future.

Co-authorship network of co-authors of Bert Klebl

This figure shows the co-authorship network connecting the top 25 collaborators of Bert Klebl. A scholar is included among the top collaborators of Bert Klebl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bert Klebl. Bert Klebl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ 2024 ·SLAS DISCOVERY ·(unknown), (unknown), (unknown), Bert Klebl, Jan Eickhoff, Christian Ottmann	0
2	An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity 2024 ·Pharmaceutics ·(unknown), Sabrina Wagner, Martin Schütz, (unknown), (unknown), Jaeseung Kim, (unknown), (unknown), Julia Tillmanns, Christina Wangen, Friedrich Hahn, Benedikt B. Kaufer, Frank Neipel, Jan Eickhoff, Bert Klebl, Kiyean Nam, Manfred Marschall	6
3	Assessment of Covalently Binding Warhead Compounds in the Validation of the Cytomegalovirus Nuclear Egress Complex as an Antiviral Target 2023 ·Cells ·Julia Tillmanns, (unknown), Eva Maria Borst, (unknown), Jan Eickhoff, Bert Klebl, Sabrina Wagner, Christina Wangen, Friedrich Hahn, Eileen Socher, Manfred Marschall	8
4	IFNα primes cancer cells for Fusicoccin-induced cell death via 14-3-3 PPI stabilization 2023 ·Cell chemical biology ·(unknown), (unknown), (unknown), Sebastian A. Andrei, (unknown), Yusuke Higuchi, Nobuo Kato, Luc Brunsveld, Michelle R. Arkin, Sascha Menninger, Axel Choidas, (unknown), Bert Klebl, Farnusch Kaschani, Markus Kaiser, Jan Eickhoff, Christian Ottmann	12
5	Characterization of the Antibacterial Activity of Quinone-Based Compounds Originating from the Alnumycin Biosynthetic Gene Cluster of a Streptomyces Isolate 2023 ·Antibiotics ·(unknown), (unknown), (unknown), Christian Rückert, Tobias Busche, Alexander Wolf, Jan Eickhoff, Bert Klebl, Jörn Kalinowski, Julia E. Bandow	3
6	A Reinvestigation of the Role of the Sorbic Acid Tail on the Antibacterial and Anti‐Tuberculosis Properties of Moiramide B 2023 ·ChemMedChem ·(unknown), (unknown), Michael Dal Molin, (unknown), (unknown), Vikram Pareek, Uwe Koch, Jan Rybniker, Nils Metzler‐Nolte, Raphael Stoll, Bert Klebl, Julia E. Bandow, Jürgen Scherkenbeck	2
7	White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer Therapy 2022 ·Cancers ·Edgar Dahl, (unknown), Peter Habenberger, Axel Choidas, Michael Rose, Bert Klebl	12
8	Structure–Activity Relationship Studies of Trisubstituted Isoxazoles as Selective Allosteric Ligands for the Retinoic-Acid-Receptor-Related Orphan Receptor γt 2021 ·Journal of Medicinal Chemistry ·Femke A. Meijer, (unknown), Richard G. Doveston, (unknown), (unknown), (unknown), Anke Unger, Bert Klebl, Christian Ottmann, Peter J. Cossar, Luc Brunsveld	9
9	Kinase Chemodiversity from the Arctic: The Breitfussins 2019 ·Journal of Medicinal Chemistry ·(unknown), Jeanette H. Andersen, Annette Bayer, (unknown), (unknown), Kåre B. Jørgensen, Magne O. Sydnes, (unknown), Matthias Baumann, Uwe Koch, Bert Klebl, Jan Eickhoff, Bengt Erik Haug, Johan Isaksson, Espen Hansen	25
10	Gasdermin D plays a vital role in the generation of neutrophil extracellular traps breakdown → 2018 ·Science Immunology ·Gabriel Sollberger, Axel Choidas, Garth L. Burn, Peter Habenberger, Raffaella Di Lucrezia, (unknown), Sascha Menninger, Jan Eickhoff, Peter Nußbaumer, Bert Klebl, Renate Krüger, Alf Herzig, Arturo Zychlinsky	571
11	Identification of Noncatalytic Lysine Residues from Allosteric Circuits via Covalent Probes 2018 ·ACS Chemical Biology ·(unknown), (unknown), Ingrid R. Vetter, Patricia Stege, (unknown), (unknown), Farnusch Kaschani, (unknown), Uwe Koch, Peter Nußbaumer, Bert Klebl, Markus Kaiser, Michael Ehrmann	8
12	Protein kinases as drug targets 2011 ·Wiley-VCH eBooks ·Bert Klebl, Gerhard Müller, Michael Hamacher	15
13	A Flexible Multiwell Format for Immunofluorescence Screening Microscopy of Small-Molecule Inhibitors 2010 ·Assay and Drug Development Technologies ·(unknown), Bert Klebl, Markus Morkel, Hans Lehrach, Andreas Dahl, Bodo Lange	2
14	Gleevec Increases Levels of the Amyloid Precursor Protein Intracellular Domain and of the Amyloid-β–degrading Enzyme Neprilysin 2007 ·Molecular Biology of the Cell ·Yvonne S. Eisele, Matthias Baumann, Bert Klebl, (unknown), Mathias Jucker, Ellen Kilger	47
15	Cellular Targets of Gefitinib 2005 ·Cancer Research ·Dirk Brehmer, Zoltán Greff, Klaus Godl, Stephanie Blencke, Alexander Kurtenbach, Martina Weber, Stefan Müller, Bert Klebl, Matthew Cotten, Gÿorgý Kéri, Josef Wissing, Henrik Daub	199
16	Second-generation kinase inhibitors 2005 ·Expert Opinion on Therapeutic Targets ·Bert Klebl, Gerhard Müller	48
17	Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages 2004 ·Science ·Anne Walburger, Anil Koul, Giorgio Ferrari, Liem Nguyen, Cristina Prescianotto‐Baschong, Kris Huygen, Bert Klebl, Charles J. Thompson, Gerald Bacher, Jean Pieters	451
18	Evaluation of Kinase Inhibitor Selectivity by Chemical Proteomics 2004 ·Assay and Drug Development Technologies ·Henrik Daub, Klaus Godl, Dirk Brehmer, Bert Klebl, Gerhard Müller	33
19	Screening Assay for the Identification of Deoxyhypusine Synthase Inhibitors 2004 ·SLAS DISCOVERY ·(unknown), Dorian Bevec, Bert Klebl, (unknown), (unknown), (unknown), Ilona Hauber, Joachim Hauber, Helmut Mett	16
20	Localization of an arginine‐specific mono‐ADP‐ribosyltransferase in skeletal muscle sarcolemma and transverse tubules 1994 ·FEBS Letters ·Bert Klebl, (unknown), Dirk Pette	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact